Single center experience with medical cannabis in Gilles de la Tourette syndrome.

INTRODUCTION: Patients with Gilles de la Tourette syndrome (GTS) experience reduced function and impaired quality of life. The current medical treatments for this syndrome can cause significant side effects and offer partial symptomatic relief. In a few small trials medical cannabis (MC) has been suggested to offer symptomatic relief with a relatively benign side effect profile. We conducted a real-life assessment of clinical benefit and adverse effects of chronic MC treatment among patients with GTS. METHODS: GTS patients treated with MC were interviewed via phone regarding treatment efficacy and side effect profile from chronic MC consumption. Global efficacy was rated on a Likert scale of 1-5 and side effects of treatment were recorded. RESULTS: Forty-Two GTS patients (33 males, mean age 34.5) were interviewed for this study. The total global impression score of efficacy was 3.85 out of a total 5 possible points. Patients reported during the free discussion part of the interview about reduction in tic severity, better sleep and improved mood as positive effects of MC. Thirty-eight patients reported any kind of benefit from treatment while 10 patients with more than one year of consumption elected to stop treatment with MC for various reasons including severe side effects as psychosis in one patient. CONCLUSION: MC seems to hold promise in the treatment of GTS as it demonstrated high subjective satisfaction by most patients however not without side effects and should be further investigated as a treatment option for this syndrome.

Deep TMS add-on treatment for intractable Tourette syndrome: A feasibility study.

OBJECTIVES: In a considerable minority of patients who suffer from Tourette syndrome (TS) the disorder persists into adulthood and is associated with severe symptoms and limited therapeutic options. Repetitive transcranial magnetic stimulation (rTMS) to the supplementary motor area (SMA) has shown promising therapeutic results. Deep rTMS is a novel technology that enables deeper non-invasive cortical stimulation. This open-label pilot study is the first to examine the possible role of deep rTMS as add-on treatment for intractable TS. METHODS: Twelve patients were recruited in order to examine bilateral SMA inhibition via deep TMS using the HBDL coil, as a possible treatment for adult TS treatment-resistant patients. Two patients did not complete the 20-day study protocol. RESULTS: There were no significant side effects. While tics did not improve among the group as a whole, the subgroup of six patients with combined TS and OCD (obsessive compulsive syndrome) showed significant improvement in tic severity (P = 0.037). CONCLUSIONS: These findings support the safety of deep rTMS for treating TS. The results also highlight the importance of studying the different TS syndromes separately (e.g., with or without OCD comorbidity) when evaluating deep rTMS protocols for TS patients.